4 results
Approved WMORecruiting
To validate that OTR4120 will improve the healing of chronic ulcers.
Approved WMORecruiting
Objective: To demonstrate the efficacy of a novel matrix therapy based technology that creates improved wound healing in a clinical donor site model.
Approved WMOCompleted
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
Approved WMOCompleted
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months